Pharmacokinetics of the treatment switch from efavirenz to nevirapine

Clinical Infectious Diseases

Volumn 50, Issue 11, 2010, Pages 1547-1548

  Parienti, Jean Jacques ^a   Peytavin, Gilles ^b   Reliquat, Véronique ^c   Verdon, Renaud ^a   Coquerel, Antoine ^a  

^a CHU CÔTE DE NACRE   (France)

^b BICHAT HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GYNECOMASTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; PSYCHOPATHY; TERATOGENICITY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; HIV INFECTIONS; HUMANS; NEVIRAPINE;

EID: 77951866323     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652718     Document Type: Letter

References (6)

1. Molina JM, Joumot V, Morand-Joubert L, et al; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team. Simplification therapy with once-daily emtridtabine, didanosine, and efavirenz in HIV-1-infected adults with, viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005; 191(6):830-839.
2. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 2006;20(8):542-548.
3. Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R; SIROCCO study team. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis 2007;45(2):263-266.
4. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS Clinical Trials Group A5095. Clin Infect Dis 2010; 50(5) :787-791.
5. Winston A, Pozniak A, Smith N, et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-I-infected individuals? AIDS 2004; 18(3):572-574.
6. Duong M, Buisson M, Peytavin G, et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother 2005; 39(4) :603609. (Pubitemid 40396611)